The nephroprotective potential of trimetazidine in chronic inflammation and oxidative stress in renal disease

Archives of Medical Science

Volumn 3, Issue 3 SUPPL. A, 2007, Pages

  Rysz, Jacek ^a   Stolarek, Robert A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Nephroprotection; Oxidative stress; Renal disease; Trimetazidine (TMZ)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; REACTIVE OXYGEN METABOLITE; TRIMETAZIDINE; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; CELL MEMBRANE; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE MODEL; DRUG BINDING; DRUG EFFECT; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MEMBRANE PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SUPPLEMENTATION;

EID: 38549131474     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 1998; 286: 23-8.
2. Elimadi A, Morin D, Sapena R, Chauvet-Monges AM, Crevat A, Tillement JP. Comparison of the effects of cyclosporine A and trimetazidine on Ca(2+)-dependent mitochondrial swelling. Fundam Clin Pharmacol 1997; 11: 440-7.
3. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93: 698-702.
4. Jayle C, Favreau F, Zhang K, et al. Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-term effects in a pig kidney model. Am J Physiol Renal Physiol 2007; 292: F1082-93.
5. Hauet T, Mothes D, Goujon J, et al. Trimetazidine reverses deleterious effects of ischemia-reperfusion in the isolated perfused pig kidney model. Nephron 1998; 80: 296-304.
6. Domanski L, Sulikowski T, Safranow K, et al. Effect of trimetazidine on the nucleotide profile in rat kidney with ischemia-reperfusion injury. Eur J Pharm Sci 2006; 27: 320-7.
7. Singh D, Chopra K. Effect of trimetazidine on renal ischemia/reperfusion injury in rats. Pharmacol Res 2004; 50: 623-9.
8. Faure JP, Baumert H, Han Z, et al. Evidence for a protective role of trimetazidine during cold ischemia: targeting inflammation and nephron mass. Biochem Pharmacol 2003; 66: 2241-50.
9. Faure JP, Petit I, Zhang K, et al. Protective roles of polyethylene glycol and trimetazidine against cold ischemia and reperfusion injuries of pig kidney graft. Am J Transplant 2004; 4: 495-504.
10. Singh D, Chander V, Chopra K. Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Toxicology 2003; 191: 43-51.
11. Goujon JM, Vandewalle A, Baumert H, Carretier M, Hauet T. Influence of cold-storage conditions on renal function of autotransplanted large pig kidneys. Kidney Int 2000; 58: 838-50.
12. Wierzbicki P, Cwetsch A, Fijałkowski P, Wańkowicz Z. Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end-stage renal failure patients treated by hemodialysis: preliminary communication [Polish]. Pol Arch Med Wewn 1999; 102: 589-94.
13. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112-9.
14. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-7.
15. Rysz J, Majewska E, Stolarek RA, Banach M, Cialkowska-Rysz A, Baj Z. Increased levels of soluble TN-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 2006; 26: 437-44.
16. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
17. Rysz J, Potargowicz E, Banach M, et al. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. Arch Immunol Ther Exp (Warsz) 2006; 54: 347-55.
18. Nowak MS, Wybor K, Gos R, et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia Arch Med Sci 2007; 3: 152-6.